Advertisement


Neha Vapiwala, MD, on Prostate Cancer: Imaging and the Decision to Treat With Radiation

2020 ASTRO Annual Meeting

Advertisement

Neha Vapiwala, MD, of the University of Pennsylvania, who served as a discussant for LBA1, summarizes her review of this study of patients with prostate cancer who had biochemical recurrence in the post-prostatectomy setting, who were candidates for salvage radiotherapy, and who received either conventional imaging or PET scans to help determine the course of treatment.



Related Videos

Prostate Cancer

Daniel E. Spratt, MD, on Prostate Cancer: Relugolix vs Leuprolide

Daniel E. Spratt, MD, of the University of Michigan Rogel Cancer Center, discusses phase III results of the HERO trial, which suggested benefits of the oral medication relugolix: a substantially faster time to castration with longer duration, fewer cardiac events, and a faster return to normal testosterone levels compared with leuroplide (Abstract 35).

Breast Cancer

Youssef Zeidan, MD, PhD, on HER2-Positive Breast Cancer: Deintensifying Radiation Therapy

Youssef Zeidan, MD, PhD, of the American University of Beirut Medical Center, discusses study findings showing that breast-conserving surgery, whole-breast irradiation, and trastuzumab offer effective local tumor control for patients with HER2-positive breast cancer. An additional radiation boost does not seem to further improve outcomes (Abstract 52).

CNS Cancers

Jeff M. Michalski, MD, MBA, on Medulloblastoma and Radiation Treatment in Pediatric Patients

Jeff M. Michalski, MD, MBA, of the Washington University School of Medicine, discusses a Children’s Oncology Group study that confirmed data previously reported: Involved-field radiotherapy is noninferior to posterior fossa radiotherapy in patients with average risk-medulloblastoma. However, low-dose craniospinal irradiation is not as effective as standard-dose irradiation in younger children (Abstract 1).

Prostate Cancer

Daniel E. Spratt, MD, on Prostate Cancer: Short-Term Adjuvant vs Neoadjuvant Hormone Therapy

Daniel E. Spratt, MD, of the University of Michigan Rogel Cancer Center, discusses a pooled analysis of two phase III trials showing adjuvant androgen-deprivation therapy (ADT) improves biochemical control and reduces distant metastasis when compared with a neoadjuvant approach, with no difference in late gastrointestinal or genitourinary toxicities. The analysis also showed that delaying radiotherapy to deliver neoadjuvant ADT did not benefit most patients (Abstract 32).

Breast Cancer

Alphonse G. Taghian, MD, PhD, on Irradiation for Breast Cancer: Defining the Optimal Dose

Alphonse G. Taghian, MD, PhD, of Massachusetts General Hospital, reviews the 10-year follow-up of a dose-escalation trial studying accelerated partial-breast irradiation and discusses the optimal dose, adverse effects, and cosmetic outcomes (Abstract 25).

Advertisement

Advertisement



Advertisement